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In this issue ofChemistry & Biology, van der Westhuyzen et al. describe the synthesis and characterization of
the natural product CJ-15,801, which acts as an antimetabolite of the coenzyme A biosynthetic pathway.The lack of new antibiotics coupled with
the increased prevalence of multidrug-
resistant bacterial pathogens is cause
for great concern (Wright, 2012). The
genomics revolution predicted a new era
in antibiotics discovery with the delivery
of an abundance of conserved and
essential targets (Payne et al., 2007).
However, target-based approaches for
antibacterial discovery have proven
quite challenging due to many problems
including conversion of a biochemical
inhibitor into a cell-permeable analog,
rapid evolution of resistance to single
targets, and potential lack of vulnerability
of a given target to inhibition (i.e., may
require >99% inhibition in order to impact
growth and/or survival). Given the histor-
ical success of natural products in the
field of antibiotics (74% of all approved
antibiotics are derived from natural prod-
ucts), revisiting abandoned and ne-
glected natural product scaffolds repre-
sents a viable strategy to overcome the
shortage of new antibiotics (Newman
and Cragg, 2012). In fact, three of the
four new antibiotic scaffolds introduced
in the last decade were all from natural
products initially discovered more than
30 years ago (e.g., fidaxomicin, a polyke-
tide; retepamulin, a diterpene; and dapto-
mycin, a lipodepsipeptide).
In this issue of Chemistry & Biology, van
der Westhuyzen et al. (2012) describe
their investigation of a natural product
antibiotic named CJ-15,801, which was
originally discovered by scientists at
Pfizer (Sugie et al., 2001). CJ-15,801
possesses promising activity against
multidrug-resistant strains of Staphylo-
coccus aureus. This microorganism is
a Gram-positive bacterium associated
with awide range of infections, fromminor
skin infections to severe cases of endo-
carditis and sepsis. Methicillin-resistant
strains of S. aureus, termed MRSA, are
particularly troublesome because of theirresistance to the classic b-lactam antibi-
otics (Gilmore et al., 2008).
CJ-15,801 (hereafter referred to as CJ)
is a dehydro analog of pantothenate
(vitamin B5), and this close structural
similarity suggests that it interferes with
coenzyme A (CoA) biosynthesis. CoA is
an essential cofactor in the central path-
ways of respiration and lipid metabolism
and is synthesized in five steps from
pantothenate (1) as shown in Figure 1
(Begley et al., 2001). The first step is
carried out by PanK (pantothenate kinase,
encoded by the gene coaA) that phos-
phorylates pantothenate to afford 40-
phosphopantothenate (2) (Hong et al.,
2006). Three PanK isoforms exist, and
S. aureus is unique among bacteria, as it
possesses a type-II PanK. PPCS (40-
phosphopantothenoylcysteine synthase,
encoded by the gene coaB) then cata-
lyzes the CTP-dependent ligation of 2
with cysteine to afford 4 (Yao et al.,
2009). Notably, this reaction proceeds
through an acyl-cytidylate intermediate
(3). Subsequent decarboxylation, adeny-
lation, and phosphorylation of 4 provides
CoA (5) through the actions of CoaC,
CoaD, and CoaE, respectively.
The authors show that CJ (6) is an
excellent substrate for PanK from
S. aureus, but not other bacterial PanKs,
and is converted into phosphorylated-CJ
(P-CJ, 7) as shown in Figure 1. P-CJ is
a substrate for PPCS, the next enzyme
in the pathway, and is efficiently cytidy-
lated to form an acyl-cytidylate interme-
diate termed P-CJ-CMP (8). However,
rather than reacting with cysteine, this
intermediate acts as a dead-end inhibitor
of PPCS. Despite the presence of the
Michael acceptor moiety, irreversible
inhibition is not observed, since enzyme
activity is restored after removing the
compound by gel filtration. Thus, CJ
innocently enters the CoA biosynthetic
pathway through PanK, then inhibits theChemistry & Biology 19, May 25, 2012second enzyme (PPCS) in the pathway,
but only after enzymatic activation to
form P-CJ-CMP. P-CJ exhibits time-
dependent inhibition of PPCS from
S. aureus with a Ki of 13 nM. The potent
Ki value is consistent with the bisubstrate
nature of P-CJ-CMP, which effectively
interacts with both the pantothenate and
CTP binding pockets. The authors
provide further overall support for inhibi-
tion of the CoA biosynthetic pathway by
showing that supplementation of the
growth media with pantothenate causes
a shift to a higher minimum inhibitory
concentration (MIC). Additionally, synergy
is observed with other CoA biosynthesis
inhibitors. Collectively, these results
reveal that CJ poisons the CoA biosyn-
thetic pathway and acts as a classic
antimetabolite. The intrinsic specificity
of CJ for S. aureus results from the
selective phosphorylation by PanK in
this organism.
The basis for PPCS inhibition by P-CJ-
CMP is intriguing, since it contains
a high energy acyl-phosphate linkage
that appears capable of reacting with
cysteine. To assess the impact of P-CJ-
CMP on protein stability, circular dichro-
ism (CD) was used tomeasure themelting
temperature (Tm) of PPCS unfolding.
P-CJ-CMP leads to enhanced protein
stability relative to the native phospho-
pantothenate-CMP intermediate 3, as
a result of the reduced conformational
entropy caused by the more rigid alkene.
The authors speculate this increased
stabilization favors a closed conformation
of the active site, which prevents the
subsequent ligation with cysteine from
occurring. Furthermore, the carbonyl
carbon of the P-CJ-CMP is proposed to
be less reactive than in 3 due to the elec-
tron-donating vinylogous amino group.
Consistent with this observation, a simple
methyl ester of CJ was resistant to
base-mediated hydrolysis. While furtherª2012 Elsevier Ltd All rights reserved 543
Figure 1. Biosynthesis of CoA and Mechanism of CJ Bioactivation
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eate the precise mechanism of inhibition
by CJ, it seems plausible that both factors
contribute to CJ’s unique reactivity.
In this article, the authors have suc-
ceeded in synthesizing CJ, elucidating
its mode of action, and uncovering
the origin of its remarkable specificity.
This work highlights the importance of
enzymology in antibiotics discovery
and reveals a conceptually elegant
mechanism of action. CJ acts as an anti-
metabolite poisoning the CoA pathway
by exploiting the promiscuity of PanK
from S. aureus to enter and then inhibit
the downstream enzyme PPCS through
formation of a catalytically incompetent
dead-end inhibitor. The sulfonamides,
the first class of antibiotics used in human544 Chemistry & Biology 19, May 25, 2012 ªmedicine, are also antimetabolites that
interfere with folate biosynthesis. Nucleo-
tidylating enzymes are ubiquitous (Duck-
worth et al., 2012), and this research
potentially offers a general strategy for
inhibiting these enzymes by incorporation
of a vinylogous carbamic acid in the
respective enzyme substrate.
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